Active — Not RecruitingNot Applicable

Liver Function Investigation With SPECT

Australia20 participantsStarted 2016-10-19

Plain-language summary

This is a Phase 1 pilot study to assess feasibility and utility of 99mTc-mebrofenin hepatobiliary scintigraphy for measurement of functional liver change due to radiotherapy.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18 or older * Has provided written Informed Consent for participation in this trial and is willing to comply with the study * Patients undergoing external beam radiotherapy at Northern Sydney Cancer Centre * Histologically proven hepatocellular carcinoma or oligometastatic liver metastases (3 or less). Histological diagnosis will be obtained if clinically indicated. * ECOG performance status 0-2 Exclusion Criteria: * Previous high-dose radiotherapy to the liver * Previous SIRT * Women who are pregnant or lactating * Unwilling or unable to give informed consent * No venous access * Inability to lie supine and still for 30 minutes * History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy (excluded from ICG testing only) * Pacemaker (excluded from Fibroscan elasticity test only)

What they're measuring

Change in global and local liver function

Timeframe: 3 years

Trial details

NCT IDNCT02967848

SponsorRoyal North Shore Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12

View on ClinicalTrials.gov More Liver Cancer, Adult trials